کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5684946 | 1597922 | 2017 | 14 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Phase 1-2 pilot clinical trial in patients with decompensated liver cirrhosis treated with bone marrow-derived endothelial progenitor cells
ترجمه فارسی عنوان
آزمایشگاهی بالینی فاز 1-2 در بیماران مبتلا به سیروز کبدی که تحت درمان با سلول های پیش گیتر آندوتلیال مغز استخوان قرار گرفته اند
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
CXCR4Acetylated-low density lipoproteinIndocyanine green clearanceHVPGVEGFRHGFICGAcLDLCT-1vWFIL-6EGFSDFIGFEPCinsulin like growth factor - انسولین مانند عامل رشدinterleukine 6 - اینترلوکین 6Endothelial progenitor cells - سلول های پیش ساز اندوتلیالStromal cell-derived factor - عامل استخراج سلول استروماepidermal growth factor - عامل رشد اپیدرمیHepatocyte growth factor - عامل رشد هپاتوسیتVon Willebrand factor - عامل فون ویلبراندVascular endothelial growth factor - فاکتور رشد اندوتلیال عروقیVascular Endothelial Growth Factor (VEGF) - فاکتور رشد اندوتلیال عروقی (VEGF)C-X-C chemokine receptor type 4 - نوع گیرنده شیمیایی C-X-C 4cardiotrophin-1 - کاردیوتروفین-1hepatic vein pressure gradient - گرادیان فشار وریدی کبدیvascular endothelial growth factor receptor - گیرنده فاکتور رشد اندوتلیال عروقی
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
پزشکی و دندانپزشکی (عمومی)
چکیده انگلیسی
The aim of this nonrandomized, open label, phase 1 clinical trial was to evaluate the safety and the feasibility of the treatment with autologous bone marrow-derived endothelial progenitor cells (EPC) in decompensated liver cirrhosis. In addition, the changes in liver function and hepatic venous pressure gradient (HVPG) and their relation with the characteristics of the cellular product were analyzed. Twelve patients with Child-Pugh â¥8 liver cirrhosis underwent bone marrow harvest for ex vivo differentiation of EPC. The final product was administered through the hepatic artery in a single administration. Patients underwent clinical and radiologic follow-up for 12 months. The phenotype and the ability to produce cytokines and growth factors of the final cellular suspension were analyzed. Eleven patients were treated (feasibility 91%). No treatment-related severe adverse events were observed as consequence of any study procedure or treatment. Model for end-stage liver disease score improved significantly (P 0.042) in the first 90 days after cells administration and 5 of the 9 patients alive at 90 days showed a decreased of HVPG. There was a direct correlation between the expression of acetylated-low density lipoprotein and von Willebrand factor in the cellular product and the improvement in liver function and HVPG. The treatment with EPCs in patients with decompensated liver cirrhosis is safe and feasible and might have therapeutic potential. Patients receiving a higher amount of functionally active EPC showed an improvement of liver function and portal hypertension suggesting that the potential usefulness of these cells for the treatment of liver cirrhosis deserves further evaluation.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Translational Research - Volume 188, October 2017, Pages 80-91.e2
Journal: Translational Research - Volume 188, October 2017, Pages 80-91.e2
نویسندگان
Delia D'Avola, Verónica Fernández-Ruiz, Francisco Carmona-Torre, Miriam Méndez, Javier Pérez-Calvo, Felipe Prósper, Enrique Andreu, José Ignacio Herrero, Mercedes Iñarrairaegui, Carmen Fuertes, José Ignacio Bilbao, Bruno Sangro, Jesús Prieto,